AAV-mediated gene therapy for heart failure: Enhancing contractility and calcium handling

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Zouein, Fouad A ^a,b   Booz, George W ^a,b  

^a School of Medicine   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE 6; CARDIOVASCULAR AGENT; G PROTEIN COUPLED RECEPTOR KINASE 2; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; PLACEBO; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

ARTICLE; ENZYME REPLACEMENT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HOSPITALIZATION; HUMAN; NONHUMAN; PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; VIRAL GENE THERAPY;

EID: 84883146827     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-27     Document Type: Article

References (60)

1. Writing Group Members, Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ,Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee; On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart Disease and Stroke Statistics- 2012 Update: A Report From the American Heart Association. Circulation 2012, 125:e2-e220.
2. Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ: Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013, Apr 8. [Epub ahead of print].
3. van Berlo JH, Maillet M, Molkentin JD: Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013, 123:37-45.
4. Distefano G, Sciacca P: Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr 2012 Sep 12, 38:41.
5. Ahn J, Kim J: Mechanisms and consequences of inflammatory signaling in the myocardium. Curr Hypertens Rep 2012, 14:510-516.
6. Sawyer DB: Oxidative stress in heart failure: what are we missing? Am J Med Sci 2011, 342:120-124.
7. 2+-ATPase and calsequestrin gene expression in the heart. Can J Physiol Pharmacol 2012, 90:1017-1028.
8. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN: Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 2003, 285:H2373-H2381. (Pubitemid 37443053)
9. 2+ leak in heart failure. Circ Res 2005, 97:1314-1322.
10. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM: Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005, 105:1424-1430. (Pubitemid 40223657)
11. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM: Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001, 75:6199-6203. (Pubitemid 32553151)
12. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003, 10:2105-2111. (Pubitemid 37536759)
13. Qi Y, Liu X, Li H, Shenoy V, Li Q, Hauswirth WW, Sumners C, Katovich MJ: Selective tropism of the recombinant adenoassociated virus 9 serotype for rat cardiac tissue. J Gene Med 2010, 12:22-34.
14. Palomeque J, Chemaly ER, Colosi P,Wellman JA, Zhou S, Del Monte F, Hajjar RJ: Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007, 14:989-997.
15. Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ: Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther 2008, 6:13.
16. Fang H, Lai NC, Gao MH, Miyanohara A, Roth DM, Tang T, Hammond HK: Comparison of Adeno-Associated Virus Serotypes and Delivery Methods for Cardiac Gene Transfer. Hum Gene Ther Methods 2012, 23:234-241.
17. Kairouz V, Lipskaia L, Hajjar RJ, Chemaly ER: Molecular targets in heart failure gene therapy: current controversies and translational perspectives. Ann N Y Acad Sci 2012, 1254:42-50.
18. Katz MG, Fargnoli AS, Pritchette LA, Bridges CR: Gene delivery technologies for cardiac applications. Gene Ther 2012, 19:659-669.
19. Gianni D, Chan J, Gwathmey JK, del Monte F, Hajjar RJ: SERCA2a in heart failure: role and therapeutic prospects. J Bioenerg Biomembr 2005, 37:375-380. (Pubitemid 43725161)
20. Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly E, Liang L, Tsuji T, Takewa Y, del Monte F, Peluso R, Zsebo K, Jeong D, Park WJ, Kawase Y, Hajjar RJ: Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 2007, 42:852-861. (Pubitemid 46527593)
21. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ: Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008, 51:1112-1119. (Pubitemid 351374774)
22. Byrne M, Power J, Preovolos A, Mariani J, Hajjar R, Kaye D: Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008, 15:1550-1557.
23. Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Kaye DM: Augmentation of left ventricular mechanics by recirculationmediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail 2011, 13:247-253.
24. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ: Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
25. 2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313.
26. Miyazaki Y, Ikeda Y, Shiraishi K, Fujimoto SN, Aoyama H, Yoshimura K, Inui M, Hoshijima M, Kasahara H, Aoki H, Matsuzaki M: Heart failureinducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling. PLoS One 2012, 7:e35875.
27. 2+ cycling. Cardiovasc Res 2011, 89:79-88.
28. Tang T, Gao MH, Hammond HK: Prospects for gene transfer for clinical heart failure. Gene Ther 2012, 19:606-612.
29. Wijnker PJ, Foster DB, Tsao AL, Frazier AH, dos Remedios CG, Murphy AM, Stienen GJ, van der Velden J: Impact of site-specific phosphorylation of protein kinase A sites Ser23 and Ser24 of cardiac troponin I in human cardiomyocytes. Am J Physiol Heart Circ Physiol 2013, 304:H260-H268.
30. Tang T, Hammond HK, Firth A, Yang Y, Gao MH, Yuan JX, Lai NC: Adenylyl cyclase 6 improves calcium uptake and left ventricular function in aged hearts. J Am Coll Cardiol 2011, 57:1846-1855.
31. Roth DM, Lai NC, Gao MH, Drumm JD, Jimenez J, Feramisco JR, Hammond HK: Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice. Am J Physiol Heart Circ Physiol 2004, 287: H172-H177. (Pubitemid 38802350)
32. Rebolledo B, Lai NC, Gao MH, Takahashi T, Roth DM, Baird SM, Hammond HK: Adenylyl cyclase gene transfer increases function of the failing heart. Hum Gene Ther 2006, 17:1043-1048. (Pubitemid 46076746)
33. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY, Spellman M, Clopton P, Hammond HK: Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 2004, 110:330-336. (Pubitemid 38955502)
34. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J, McKirnan MD, Kwong C, Dalton N, Urasawa K, Roth DA, Hammond HK: Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 2000, 102:2396-2401.
35. Reinkober J, Tscheschner H, Pleger ST, Most P, Katus HA, Koch WJ, Raake PW: Targeting GRK2 by gene therapy for heart failure: benefits above b-blockade. Gene Ther 2012, 19:686-693.
36. Kranias EG, Hajjar RJ: Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012, 110: 1646-1660.
37. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E, Park WJ, Hajjar RJ: SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011, 477:601-605.
38. Shenoy SK, Rockman HA: Cardiovascular biology: heart fails without pump partner. Nature 2011, 477:546-547.
39. Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D, Löffler E, Janssen PM, Eckhart AD, Martini J, Williams ML, Katus HA, Remppis A, Koch WJ: Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004, 114:1550-1563. (Pubitemid 40385546)
40. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ: Stable myocardial-specific AAV6- S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007, 115:2506-2515. (Pubitemid 46763224)
41. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Müller OJ, Most P: Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011, 3:92ra64.
42. Anversa P, Kajstura J, Rota M, Leri A: Regenerating new heart with stem cells. J Clin Invest 2013, 123:62-70.
43. Pal SN, Kofidis T: New cell therapies in cardiology. Expert Rev Cardiovasc Ther 2012, 10:1023-1037.
44. Kikuchi K, Poss KD: Cardiac regenerative capacity and mechanisms. Annu Rev Cell Dev Biol 2012, 28:719-41.
45. Chong JJ: Cell therapy for left ventricular dysfunction: an overview for cardiac clinicians. Heart Lung Circ 2012, 21:532-542.
46. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG; on behalf of the American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Pr: Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. Circ Heart Fail 2013, Apr 24. [Epub ahead of print].
47. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ, Koch WJ: In vivo ventricular gene delivery of a b-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103: 1311-1316. (Pubitemid 32221357)
48. Tevaearai HT, Walton GB, Keys JR, Koch WJ, Eckhart AD: Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the b-adrenergic receptor kinase (bARK1). J Gene Med 2005, 7:1172-1177. (Pubitemid 41341187)
49. Katz MG, Fargnoli AS, Swain JD, Tomasulo CE, Ciccarelli M, Huang ZM, Rabinowitz JE, Bridges CR: AAV6-bARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg 2012, 143:720-726.
50. Swain JD, Fargnoli AS, Katz MG, Tomasulo CE, Sumaroka M, Richardville KC, Koch WJ, Rabinowitz JE, Bridges CR: MCARDmediated gene transfer of GRK2 inhibitor in bovine model of acute myocardial infarction. J Cardiovasc Transl Res 2013, 6:253-262.
51. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ: Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119:89-98.
52. Dieterle T, Meyer M, Gu Y, Belke DD, Swanson E, Iwatate M, Hollander J, Peterson KL, Ross J Jr, Dillmann WH: Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005, 67:678-688. (Pubitemid 41033363)
53. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R, Mariani JA, Pepe S, Chien KR, Power JM: Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007, 50:253-260. (Pubitemid 47031573)
54. Andino LM, Takeda M, Kasahara H, Jakymiw A, Byrne BJ, Lewin AS: AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J Gene Med 2008, 10:132-42. (Pubitemid 351267155)
55. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, Chien KR: Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002, 8:864-871.
56. 2+- ATPase activity and cardiac dysfunction in rats with myocardial infarction. Eur J Heart Fail 2008, 10:47-54.
57. Zhang HS, Liu D, Huang Y, Schmidt S, Hickey R, Guschin D, Su H, Jovin IS, Kunis M, Hinkley S, Liang Y, Hinh L, Spratt SK, Case CC, Rebar EJ, Ehrlich BE, Gregory PD, Giordano FJ: A designed zincfinger transcriptional repressor of phospholamban improves function of the failing heart. Mol Ther 2012, 20:1508-1515.
58. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, Wang L, Aoki H, Matsuzaki M: Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 2006, 20:1197-1199.
59. Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Kaye DM: Augmentation of left ventricular mechanics by recirculationmediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail 2011, 13:247-53.
60. Beeri R, Chaput M, Guerrero JL, Kawase Y, Yosefy C, Abedat S, Karakikes I, Morel C, Tisosky A, Sullivan S, Handschumacher MD, Gilon D, Vlahakes GJ, Hajjar RJ, Levine RA: Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 2010, 3:627-634.